Report Description Table of Contents Methodology Segmentation Alzheimer’s Disease Therapeutics and Diagnostics Market Overview The global market for Alzheimer’s disease therapeutics and diagnostics is entering a pivotal phase. In 2024, it was valued at USD 11.40 billion and is expected to grow to USD 19.44 billion by 2030, reflecting a CAGR of 9.3%. This expansion is fueled by a shift from symptom-focused care to early intervention strategies and precision-based diagnostic tools. Market Dynamics Market Drivers Increasing prevalence of Alzheimer’s disease Alzheimer’s disease (AD) is primarily age-related, affecting about 5% of individuals aged 65–74, 13.1% of those aged 75–84, and 33.3% of people aged 85 and above. The global trend of aging populations has led to a rise in AD cases, indicating a future surge in affected individuals. Worldwide, the estimated number of people with AD dementia, prodromal AD, and preclinical AD stands at 32 million, 69 million, and 315 million respectively, totaling 416 million across the AD spectrum. In 2021, approximately 57 million people globally were living with dementia, with over 60% residing in low- and middle-income nations. Alzheimer’s disease, the most common form of dementia, may account for 60–70% of these cases. Mild cognitive impairment (MCI) affects around 22% of individuals over 65, with AD being the root cause in nearly half of these instances. According to the European Brain Council, around 7 million people in Europe are living with Alzheimer’s disease. In Spain, the number exceeds 0.8 million. In 2024, an estimated 6.9 million Americans aged 65 and older were living with Alzheimer’s dementia, with 73% of them aged 75 or older. Global costs associated with dementia care are estimated to exceed $818 billion annually and are projected to surpass $2 trillion by 2028. Market Opportunities Advances in diagnostic technologies Artificial intelligence (AI) is increasingly being applied to manage neurodegenerative diseases, offering new possibilities for improving dementia diagnosis and treatment of complex neurological conditions. Researchers are using AI-powered databases to accelerate drug discovery and analyze large biomedical datasets more efficiently. AI research spans various domains, with a strong emphasis on machine learning (ML) and deep learning (DL). Companies are combining knowledge graphs with retrieval-augmented generation (RAG) to enhance general-purpose AI models from providers like Anthropic and OpenAI. AI systems can also integrate with vector databases, which represent data as vectors. Healthcare and life sciences organizations benefit from organizing diverse data sources into relational maps rather than traditional databases. Deep learning tools can evaluate drug effectiveness by examining drug-inhibitor interactions, supporting personalized medicine. Future developments are expected to yield more advanced and portable tools for predicting, diagnosing, and treating Alzheimer’s disease. Growing investment in research and development Investor / Funder Recipient / Program Investment Amount Purpose / Focus Area Date Novo Holdings Asceneuron (Switzerland) $100 million Phase 2 development of ASN51, an O-GlcNAcase inhibitor targeting tau pathology in AD July 2024 Alzheimer’s Drug Discovery Foundation (ADDF) C2N Diagnostics (USA) $7 million+ Development of scalable blood-based p-Tau217 biomarker tests for early AD detection September 2024 UK Government National Neurodegeneration Initiative £160 million/year Expansion of dementia research funding; aims to recruit 500,000 volunteers for clinical trials Ongoing through 2025 Eisai & Biogen Global rollout of Leqembi (lecanemab) Undisclosed Commercial launch and infrastructure development for anti-amyloid therapy in multiple regions 2024–2025 Eli Lilly Development of donanemab and remternetug Undisclosed Clinical trials and regulatory submissions for anti-amyloid monoclonal antibodies 2024–2025 Roche & Quanterix Collaboration on plasma amyloid beta testing Undisclosed Development and validation of blood-based biomarkers to replace costly PET/CSF tests 2024–2025 C2N Diagnostics Partnership with Alector & Eisai Undisclosed Commercialization of FDA breakthrough-designated plasma amyloid beta 42/40 ratio test 2024–2025 Alzheimer’s Disease Drug Development Pipeline As of January 2024, there were 164 clinical trials underway for Alzheimer’s disease, covering prevention, mild cognitive impairment (MCI), and AD dementia, involving 127 unique drug candidates. These included 48 trials testing 32 drugs in Phase 3, 90 trials evaluating 81 drugs in Phase 2, and 26 trials assessing 25 drugs in Phase 1. Over the past five years, Alzheimer’s clinical research has seen a resurgence, supported by deeper insights into disease biology, enhanced biomarker use, and stronger regulatory and investor backing for disease-modifying therapies (DMTs). As of April 2025, the global Alzheimer’s pipeline includes: 495 active clinical trials, up from 470 in early 2024 127 drug candidates in development Trials conducted in over 24 countries, with growing focus on diverse populations and earlier disease stages Despite historically high failure rates of 98–99.6%, the current momentum reflects a turning point toward more targeted therapies and adaptive trial designs. Product Name Generic Name Company Mechanism of Action Approval Type Approval Year Status (Apr 2025) Key Notes Leqembi Lecanemab Eisai / Biogen Anti-amyloid beta mAb Accelerated + Full 2023 Approved & marketed First FDA-approved fully approved anti-amyloid DMT Kisunla Donanemab Eli Lilly Anti-amyloid beta mAb Full 2024 Approved & marketed Demonstrates ~29% cognitive slowing; approved for early-stage AD Aduhelm Aducanumab Biogen Anti-amyloid beta mAb Accelerated 2021 Withdrawn (2024) Approval withdrawn due to limited uptake and controversy Regulatory Approvals FDA has approved multiple therapies for Alzheimer’s disease, including Leqembi and Kisunla, while Aduhelm was withdrawn in 2024. Recent Developments On April 15, 2025, Eisai and Biogen announced that the European Commission granted Marketing Authorization for Leqembi (lecanemab) in the EU, marking the first approval of a therapy targeting the root cause of Alzheimer’s disease. On March 28, 2025, the EU regulator declined approval for Eli Lilly’s Kisunla, citing that the cognitive benefits did not sufficiently outweigh the risk of severe brain swelling. Concerns have also been raised about the affordability of Leqembi in European markets, where the U.S. price is $26,500 annually. A Northwestern University study found that NU-9, a small-molecule drug approved for ALS trials, also improves neuron health in Alzheimer’s animal models. The findings were published in the Proceedings of the National Academy of Sciences. On July 2, 2024, the U.S. FDA approved Kisunla for treating early symptomatic Alzheimer’s disease, including MCI and mild dementia stages with confirmed amyloid pathology. Kisunla is administered monthly and has a U.S. list price of approximately $32,000, generating $9.3 million in sales in 2024. Market Segmentation By Product Diagnostics Biomarker analysis Imaging techniques (MRI, PET) Genetic testing Digital diagnostics Blood-based assays Therapeutics Cholinesterase inhibitors NMDA receptor antagonists Anti-amyloid monoclonal antibodies Tau aggregation inhibitors Disease-modifying therapies By Region North America Asia-Pacific Europe Latin America Middle East & Africa Regional Analysis – Alzheimer’s Disease Therapeutics And Diagnostics Market North America Market Trends In 2024, North America dominated the global Alzheimer’s disease therapeutics and diagnostics market, representing around USD 5.8 billion—over half of the total market share. The US has one of the highest Alzheimer’s patient burdens globally, with an estimated 6.7 million individuals affected by the disease. A strong R&D ecosystem, combined with an efficient regulatory framework, has facilitated rapid FDA approvals & enhanced clinical trial capabilities. Government support, particularly through Medicare & CMS reimbursement expansions for PET imaging & cognitive screening, further strengthens the healthcare infrastructure. Additionally, the presence of major biopharmaceutical companies like Biogen, Eli Lilly & Eisai ensures continuous advancements in therapeutics and diagnostics. High levels of awareness and improved diagnostic accessibility contribute to early detection efforts, with initiatives focused on blood-based biomarker development & cognitive health programs leading the way. Europe Market Developments Approximately 7 million people in Europe currently live with Alzheimer’s disease, and as the population ages, it has become an increasing global public health concern. This figure is expected to double, reaching 14 million by 2030. The societal & economic impact of dementia in Europe is substantial, with costs projected to exceed EUR 250 billion by 2030, over half of which will stem from informal care expenses. Currently, healthcare systems across Europe face limitations in effectively detecting, diagnosing, and treating AD. During Brain Awareness Week 2023, the European Brain Council (EBC) & the European Federation of Pharmaceutical Industries and Associations (EFPIA) introduced the Rethinking Alzheimer’s Disease White Paper, advocating for improvements in Alzheimer’s detection and diagnosis. The European Federation of Pharmaceutical Industries & Associations (EFPIA) supports the RETHINKING Alzheimer’s Disease. Asia-pacific Growth Opportunities According to the Alzheimer’s International study, the number of people with dementia in the APAC region is projected to triple by 2050. By mid-century, this region will account for more than half of the global dementia population. Across Asian regions, East Asia has the highest estimated number of individuals with Aβ-positive Alzheimer's disease dementia at 6.6 million, followed by South Asia with 3.9 million, high-income Asia Pacific regions with 2.5 million, and Southeast Asia with 2.4 million. With over 20 million individuals affected by dementia in the region and a rapidly aging population, the healthcare burden is immense. Addressing this challenge will require focused research and workforce education to enhance prevention strategies through health promotion. Emerging markets in Latin America Latin American countries face rising prevalence & incidence of Alzheimer's disease and related dementias (ADRD), driven by a rapid demographic transition & the accelerated growth of their aging populations. In 2023, the Alzheimer's Association held its eighth satellite symposium in Mexico, showcasing advancements in dementia research, key priorities, and challenges across Latin America. Acknowledging both the challenges and scientific opportunities in the region, the Alzheimer's Association allocated funding in 2023 to support 41 active research grants across Latin America, amounting to over $4 million. Middle East & Africa diagnostics expansion Alzheimer's disease (AD) imposes a significant economic burden on societies, leading to rising healthcare expenses, long-term care costs & diminished productivity. A 2019 study estimated that dementia care in the MENA region amounted to approximately $2.1 billion, with expenditures growing at an annual rate of 8.2% since 2000. By 2050, costs are projected to surge to $57.9 billion. Key Players in the Alzheimer’s Disease Therapeutics And Diagnostics Market Biogen Pfizer Eisai Co., Ltd. Eli Lilly Roche Grifols Johnson & Johnson TauRx Therapeutics Novartis Novo Nordisk Alzheimer’s Disease Therapeutics and Diagnostics Market Report Coverage Report Attribute Details Forecast Period 2024 – 2032 Market Size Value in 2024 USD 11.40 Billion Revenue Forecast in 2030 USD 19.44 Billion Overall Growth Rate CAGR of 9.3% (2024 – 2030) Base Year for Estimation 2023 Historical Data 2017 – 2021 Unit USD Million, CAGR (2024 – 2030) Segmentation By Product, By Geography By Product Diagnostics: Biomarker Analysis, Imaging Techniques (MRI, PET), Genetic Testing, Digital Diagnostics, Blood-Based Assays Therapeutics: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies, Tau Aggregation Inhibitors, Disease-Modifying Therapies By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Germany, China, Japan, India, UK, Brazil, etc. Market Drivers Aging population, advancements in diagnostic technologies, increasing R&D investment Pricing and Purchase Options Customization available upon request Table of Contents Executive Summary • Market Overview • Market Attractiveness by Light Source, Mounting Type, Component, Application, and Region • Strategic Insights from Key Executives (CXO Perspective) • Historical Market Size and Future Projections (2022–2032) • Summary of Market Segmentation by Light Source, Mounting Type, Component, Application, and Region Market Share Analysis • Leading Players by Revenue and Market Share • Market Share Analysis by Light Source, Mounting Type, and Application Investment Opportunities in the Cleanroom Lighting Market • Key Developments and Innovations • Mergers, Acquisitions, and Strategic Partnerships • High-Growth Segments for Investment Market Introduction • Definition and Scope of the Study • Market Structure and Key Findings • Overview of Top Investment Pockets Research Methodology • Research Process Overview • Primary and Secondary Research Approaches • Market Size Estimation and Forecasting Techniques Market Dynamics • Key Market Drivers • Challenges and Restraints Impacting Growth • Emerging Opportunities for Stakeholders • Impact of Macroeconomic and Technological Factors • COVID-19 and Post-Pandemic Analysis Global Cleanroom Lighting Market Analysis • Historical Market Size and Volume (2022–2032) • Market Size and Volume Forecasts (2024–2032) • Market Analysis by Light Source: o LED o Fluorescent o Incandescent • Market Analysis by Mounting Type: o Teardrop o Recessed o Surface Mount o Integral Ceiling Grid • Market Analysis by Component: o Hardware o Software o Services • Market Analysis by Application: o Pharmaceutical Industry o Semiconductor Processing o Electronic & Precision Engineering Facilities o Food & Beverage Industry o Hospital & Veterinary Premises o Chemical & Biological Labs o Others • Market Analysis by Region: o North America o Europe o Asia-Pacific o Latin America o Middle East & Africa North America Cleanroom Lighting Market Analysis • Historical Market Size and Volume (2022–2032) • Market Size and Volume Forecasts (2024–2032) • Market Analysis by Light Source • Market Analysis by Mounting Type • Market Analysis by Component • Market Analysis by Application • Country-Level Breakdown: o United States o Canada o Mexico Europe Cleanroom Lighting Market Analysis • Historical Market Size and Volume (2022–2032) • Market Size and Volume Forecasts (2024–2032) • Market Analysis by Light Source • Market Analysis by Mounting Type • Market Analysis by Component • Market Analysis by Application • Country-Level Breakdown: o Germany o United Kingdom o France o Italy o Spain o Rest of Europe Asia-Pacific Cleanroom Lighting Market Analysis • Historical Market Size and Volume (2022–2032) • Market Size and Volume Forecasts (2024–2032) • Market Analysis by Light Source • Market Analysis by Mounting Type • Market Analysis by Component • Market Analysis by Application • Country-Level Breakdown: o China o India o Japan o South Korea o Rest of Asia-Pacific Latin America Cleanroom Lighting Market Analysis • Historical Market Size and Volume (2022–2032) • Market Size and Volume Forecasts (2024–2032) • Market Analysis by Light Source • Market Analysis by Mounting Type • Market Analysis by Component • Market Analysis by Application • Country-Level Breakdown: o Brazil o Argentina o Rest of Latin America Middle East & Africa Cleanroom Lighting Market Analysis • Historical Market Size and Volume (2022–2032) • Market Size and Volume Forecasts (2024–2032) • Market Analysis by Light Source • Market Analysis by Mounting Type • Market Analysis by Component • Market Analysis by Application • Country-Level Breakdown: o GCC Countries o South Africa o Rest of Middle East & Africa Key Players and Competitive Analysis • Signify N.V. – Global Leader in Cleanroom Lighting Solutions • Wipro Lighting – Provider of Energy-Efficient Cleanroom Lighting • Acuity Brands, Inc. – Innovator in Cleanroom and High-Performance Lighting Systems • Havells India Ltd. – Leading Supplier of Cleanroom Lighting Solutions • Solite Europe Ltd. – Expertise in Cleanroom and Industrial Lighting • Terra Universal, Inc. – Manufacturer of Cleanroom Lighting and Equipment • Kenall Manufacturing – Specializing in Cleanroom and Specialty Lighting Systems • Isoone Cleanroom Lighting – Focused on Cleanroom Lighting for Critical Environments • Astra Lighting – Innovator in Daylighting and Cleanroom Lighting Solutions • Lug Light Factory – Leading Provider of Cleanroom Lighting Solutions Appendix • Abbreviations and Terminologies Used in the Report • References and Sources List of Tables • Market Size by Light Source, Mounting Type, Component, Application, and Region (2024–2032) • Regional Market Breakdown by Light Source, Mounting Type, and Application (2024–2032) List of Figures • Market Dynamics: Drivers, Restraints, Opportunities, and Challenges • Regional Market Snapshot for Key Regions • Competitive Landscape and Market Share Analysis • Growth Strategies Adopted by Key Players • Market Share by Light Source, Mounting Type, and Application (2024 vs. 2032) . Market Segmentation By Product Diagnostics Therapeutics By Diagnostic Method Biomarker Analysis Imaging (MRI, PET) Genetic Testing Blood-Based Assays By Therapeutic Class Cholinesterase Inhibitors NMDA Antagonists Anti-Amyloid Monoclonal Antibodies (mAbs) Tau Inhibitors Disease-Modifying Therapies (DMTs) By End-User Hospitals Specialty Clinics Home Testing By Region North America Europe Asia-Pacific Latin America Middle East & Africa Reimbursement & Treatment Economics The reimbursement landscape for Alzheimer’s disease therapeutics and diagnostics is evolving rapidly, influenced by regulatory approvals, payer policies, and healthcare infrastructure. In the U.S., Medicare and Medicaid have expanded coverage for PET imaging and biomarker tests, facilitating earlier diagnosis and treatment initiation. However, reimbursement rates vary significantly across regions and payers, impacting patient access and market uptake. Treatment economics are shaped by high drug costs, especially for novel disease-modifying therapies like anti-amyloid monoclonal antibodies, which can exceed $25,000 annually per patient. Cost-effectiveness analyses and health technology assessments are increasingly used by payers to determine coverage decisions. Innovative payment models, including outcomes-based agreements and risk-sharing, are being explored to balance affordability with incentivizing innovation. Globally, disparities in reimbursement policies and healthcare funding create challenges for equitable access, particularly in low- and middle-income countries. Ongoing efforts aim to harmonize reimbursement frameworks and improve economic evaluations to support sustainable market growth. Forecast Period 2025–2032